Replies to post #73148 on Innovation Pharmaceuticals Inc (IPIX)

[F1ash]

Did you forget we have a middle child "P"? Or do you just not like her much?

[CallMeCrazy]

BK, I posted this a week ago, perhaps you care to respond.
CallMeCrazy Friday, 10/03/14 07:34:49 PM
Re: None
Post # of 73162

Can someone take a look at this partnership deal and tell me why CTIX shouldn't do as good or better with B?


Quote:
MannKind Corporation’s (MNKD - Analyst Report) search for a partner to market its only approved product Afrezza ended with the company inking a global licensing deal with French company Sanofi (SNY - Analyst Report). Afrezza was cleared by the FDA in Jun 2014 for the improvement of glycemic control in adults suffering from diabetes mellitus.



Now here's the deal:


Quote:
The deal will boost MannKind’s balance sheet substantially. The U.S. based company will receive an upfront payment of $150 million under the deal. Furthermore, MannKind is eligible to receive milestone payments of up to $775 million. MannKind is eligible to receive 35% of the global profits/losses emanating from Afrezza sales. Sanofi will get the balance. Under the terms of the deal, Sanofi will advance to MannKind its share of the partnership's expenses of up to $175 million.



Obviously, Afrezza has FDA approval and B does not and this agreement confers worldwide rights for commercial, regulatory and development activities, but this still seems like an awfully good deal.

Comments please.

http://www.zacks.com/stock/news/143439/MannKind-Enters-into-a-Global-Deal-with-Sanofi-for-Afrezza